Literature DB >> 10691994

Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis.

A A Vrij1, J Rijken, J W Van Wersch, R W Stockbrügger.   

Abstract

BACKGROUND: As platelet factors are important in the inflammatory response, we examined the course of platelet factor 4 and beta-thromboglobulin in relation to disease activity in inflammatory bowel disease and in giant cell arteritis. PATIENTS AND METHODS: In a prospective study, the platelet count, platelet factor 4 and beta-thromboglobulin were measured in 20 patients with Crohn's disease, 18 with ulcerative colitis and 19 with giant cell arteritis, during active and inactive disease, as well as in 51 controls without inflammation.
RESULTS: Platelet counts were significantly higher in active vs. inactive Crohn's disease, ulcerative colitis and giant cell arteritis. Levels of platelet factor 4 and beta-thromboglobulin were significantly higher in active inflammatory bowel disease and giant cell arteritis, as well as in inactive inflammatory bowel disease and giant cell arteritis, than in the non-inflammatory controls. A positive correlation was found between the Crohn's disease activity index and the platelet count, platelet factor 4 and beta-thromboglobulin. Also, a positive correlation was found between the ulcerative colitis activity index and beta-thromboglobulin. However, even after 12 months of follow-up, in Crohn's disease and ulcerative colitis the mean levels of platelet factor 4 and beta-thromboglobulin were significantly higher than the levels of the controls.
CONCLUSION: Platelet factors were correlated with inflammatory bowel disease activity. Levels of platelet factor 4 and beta-thromboglobulin, however, were markedly raised for a long time in clinically inactive inflammatory bowel disease, which might point to a pre-thrombotic state of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691994     DOI: 10.1046/j.1365-2362.2000.00616.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  17 in total

1.  Increased aggregation response of platelets in patients with inflammatory bowel disease.

Authors:  Akira Andoh; Takashi Yoshida; Yuki Yagi; Shigeki Bamba; Kazunori Hata; Tomoyuki Tsujikawa; Katsuyuki Kitoh; Masaya Sasaki; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

2.  Reticulated platelet levels in patients with ulcerative colitis.

Authors:  Hasan Kayahan; Mesut Akarsu; Mehmet Ali Ozcan; Serdal Demir; Halil Ates; Belkis Unsal; Hale Akpinar
Journal:  Int J Colorectal Dis       Date:  2007-06-05       Impact factor: 2.571

3.  Generation and Characterization of a New Monoclonal Antibody Against CXCL4.

Authors:  Jing Gao; Mingyuan Wu; Jin Gao; Xia Wang; Yang Zhang; Shunying Zhu; Yan Yu; Wei Han
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-04

4.  Fibrinogen-like protein 2 prothrombinase may contribute to the progression of inflammatory bowel disease by mediating immune coagulation.

Authors:  Xiu-Li Dong; Hai-Hua Lin; Ren-Pin Chen; Huan-Dong Zhou; Wan-Dong Hong; Xiang-Rong Chen; Qing-Ke Huang; Xue-Cheng Sun; Zhi-Ming Huang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

5.  Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.

Authors:  Hélène F E Gleitz; Aurélien J F Dugourd; Nils B Leimkühler; Inge A M Snoeren; Stijn N R Fuchs; Sylvia Menzel; Susanne Ziegler; Nicolaus Kröger; Ioanna Triviai; Guntram Büsche; Hans Kreipe; Bella Banjanin; Jessica E Pritchard; Remco Hoogenboezem; Eric M Bindels; Neele Schumacher; Stefan Rose-John; Shannon Elf; Julio Saez-Rodriguez; Rafael Kramann; Rebekka K Schneider
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

6.  Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.

Authors:  Hiroshi Takeyama; Tsunekazu Mizushima; Hideki Iijima; Shinzaki Shinichiro; Mamoru Uemura; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2015-06-16       Impact factor: 3.199

7.  Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.

Authors:  Anton A Vrij; Ardi Oberndorff-Klein-Woolthuis; Gerard Dijkstra; Andrea E de Jong; Rob Wagenvoord; Hendrik C Hemker; Reinhold W Stockbrügger
Journal:  J Thromb Thrombolysis       Date:  2007-02-17       Impact factor: 2.300

8.  Critical role of CXCL4 in the lung pathogenesis of influenza (H1N1) respiratory infection.

Authors:  L Guo; K Feng; Y C Wang; J J Mei; R T Ning; H W Zheng; J J Wang; G S Worthen; X Wang; J Song; Q H Li; L D Liu
Journal:  Mucosal Immunol       Date:  2017-01-25       Impact factor: 7.313

9.  Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis.

Authors:  Wei-Guo Dong; Shao-Ping Liu; Hai-Hang Zhu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

10.  Exogenous CXCL4 infusion inhibits macrophage phagocytosis by limiting CD36 signalling to enhance post-myocardial infarction cardiac dilation and mortality.

Authors:  Merry L Lindsey; Mira Jung; Andriy Yabluchanskiy; Presley L Cannon; Rugmani Padmanabhan Iyer; Elizabeth R Flynn; Kristine Y DeLeon-Pennell; Fritz M Valerio; Courtney L Harrison; Crystal M Ripplinger; Michael E Hall; Yonggang Ma
Journal:  Cardiovasc Res       Date:  2019-02-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.